Document is current

Any future updates will be listed below

Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction

Crossref DOI link: https://doi.org/10.1007/s00228-016-2109-y

Published Online: 2016-08-10

Published Print: 2016-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark